Anders Edvell News Today

Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the...

Gothenburg, Sweden, June 7, 2023 - Isofol Medical AB announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of... | June 7, 2023

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland...

Immedica Pharma AB (“Immedica”) and Japanese company OrphanPacific, Inc. (“OrphanPacific”) are happy to announce that they on May 2, 2022, entered an...

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for...

31 dicembre 2020 08:22 Fonte: Adnkronos #chimica-e-farmacia STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti® is in Europe and North...

Share this article Share this article STOCKHOLM and HANGZHOU, China, Dec. 30, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti ® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti ® is in Europe and North America indicated f...

(1) STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti is in Europe and North America indicated for treatment of urea cycle disorders (UC...